Source: Ophthalmology
Area: News
According to data from the VIEW 1 and VIEW 2 studies published early online in Ophthalmology, and presented at the American Academy of Ophthalmology annual meeting, intravitreal aflibercept dosed monthly or every 2 months after 3 initial monthly doses produced similar efficacy and safety outcomes as monthly ranibizumab.
The similarly designed phase III studies involved a total of 2,419 patients with active, subfoveal, choroidal neovascularization (CNV) lesions (or juxtafoveal lesions with leakage affecting the fovea) secondary to AMD who were randomised to intravitreal aflibercept 0.5 (Read more...)
Uncategorized